×
About 6,880 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  2,281 results

Venous thromboembolism during systemic inflammatory and autoimmune diseases associated ...
https://doi.org/10.55563/clinexprheumatol/nbn38d
Clinical and Experimental Rheumatology; Péan de Ponfilly-Sotier M, Jachiet V et. al.

May 18th, 2022 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML) are associated with systemic inflammatory and autoimmune diseases (SIADs) in 10-30% of cases. The aims of this study were (i) to evaluate the prevalence of venous thromboe...

Beyond the routine CBC: machine learning and statistical analyses identify research CBC...
https://doi.org/10.1136/jclinpath-2021-207860
Journal of Clinical Pathology; Pozdnyakova O, Niculescu RS et. al.

May 17th, 2022 - Given the time, expense and clinical expertise required for a myelodysplastic syndrome (MDS) diagnosis, there is a clear need for a cost-effective screening laboratory test that can rapidly and accurately distinguish patients with cytopenias relat...

Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: ...
https://doi.org/10.1080/17474086.2022.2077721
Expert Review of Hematology; Finelli C, Parisi S et. al.

May 14th, 2022 - Anemia is often present in mostly elderly patients with myelodysplastic syndromes (MDS), and is associated with a poorer outcome. Although Red blood cell (RBC) transfusions are the most immediate treatment, waiting for the response to disease-spec...

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

May 13th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

see more →

Guidelines  12 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 23rd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 4th, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Myelodysplastic syndromes: clinical practice guidelines in oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000017
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

see more →

Drugs  38 results see all →

Clinicaltrials.gov  153 results

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

May 13th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05371730

May 12th, 2022 - This is a single arm, open-label, single-center pilot study. In this study, 15 patients will be enrolled. The primary purpose is to explore the safety including incidence of adverse events and serious adverse events.The secondary purpose is to exp...

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myel...
https://clinicaltrials.gov/ct2/show/NCT04994808

May 11th, 2022 - OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine IV over 30 minutes on days -6 to -2. Patients also undergo total-body irradiation (TBI) followed b...

Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
https://clinicaltrials.gov/ct2/show/NCT05367583

May 10th, 2022 - Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders due to qualitative defects of the hematopoietic stem cell, resulting in uneffective hematopoiesis, dysplasia of one or more lineages, and subsequently, various cytopeni...

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomono...
https://clinicaltrials.gov/ct2/show/NCT05365035

May 6th, 2022 - Primary Objectives: To determine the efficacy, safety and tolerability of the combination of cladribine, cytarabine and venetoclax in higher-risk MDS with excess blasts and higher-risk CMML. MDS relapsed cohort (Cohort A, N=20): MDS with Int-2 or ...

see more →

News  265 results

Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies
https://www.onclive.com/view/yale-scientists-discover-a-new-pathogenic-mechanism-in-hematological-malignancies

Apr 22nd, 2022 - Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Approximately half the patients diagnosed with MD...

Treosulfan-Based Conditioning Improves Survival in Elderly, Comorbid Patients With AML
https://www.onclive.com/view/treosulfan-based-conditioning-improves-survival-in-elderly-comorbid-patients-with-aml

Apr 15th, 2022 - Treatment with a treosulfan-based conditioning regimen led to a superior event-free and overall survival (OS) compared with busulfan-based conditioning in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transpla...

BRCA, HRD Testing Are Essential in Up-front Advanced Ovarian Cancer Management
https://www.onclive.com/view/brca-hrd-testing-are-essential-in-up-front-advanced-ovarian-cancer-management

Mar 1st, 2022 - The first decision in newly diagnosed, advanced ovarian cancer is whether to pursue primary debulking or neoadjuvant chemotherapy, determined in part by the presence of pleural effusion, significant ascites, and diffusely metastatic disease. Howev...

FDA Grants Orphan Drug Designation to Eltanexor for Myelodysplastic Syndromes
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-eltanexor-for-myelodysplastic-syndromes

Feb 28th, 2022 - The FDA has granted an orphan drug designation to eltanexor (KPT-8602), an investigational novel SINE compound, as a potential therapeutic option for patients with myelodysplastic syndromes (MDS), according to an announcement from Karyopharm Thera...

Oral Decitabine Plus Cedazuridine Combo Shows Promise in Lower-Risk MDS
https://www.onclive.com/view/oral-decitabine-plus-cedazuridine-combo-shows-promise-in-lower-risk-mds

Feb 28th, 2022 - The combination of oral decitabine and cedazuridine (Inqovi) was well tolerated and provided potentially promising outcomes in patients with lower-risk myelodysplastic syndromes (MDS), according to results from the phase 3 ASCERTAIN trial (NCT0330...

see more →

Patient Education  3 results see all →